Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.72 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | CASP6 | P55212 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 7/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8427051 | 0.90 | CA2 (0.62) | APEX1CA2ALDH1A1MAPTLMNA | |
| SCHEMBL1996412 | 0.87 | APEX1 (0.70) | APEX1CA2CASP6ALDH1A1MAPT | |
| SCHEMBL8422374 | 0.85 | APEX1 (0.71) | APEX1CA2CASP6ALDH1A1MAPT | |
| SCHEMBL8102330 | 0.83 | HPGD (0.60) | APEX1CA2ALDH1A1MAPTLMNA | |
| SCHEMBL8215970 | 0.83 | APEX1 (0.65) | APEX1CASP6ALDH1A1MAPTTSHR | |
| SCHEMBL1025382 | 0.81 | APEX1 (0.69) | APEX1CASP6ALDH1A1MAPTTSHR | |
| SCHEMBL832001 | 0.80 | ALDH1A1 (0.71) | CA2ALDH1A1MAPTTSHRTDP1 | |
| SCHEMBL12291532 | 0.79 | CA2 (0.63) | APEX1CA2ALDH1A1MAPTTDP1 | |
| SCHEMBL8285548 | 0.79 | CA2 (0.63) | APEX1CA2ALDH1A1MAPTTSHR | |
| SCHEMBL11876450 | 0.79 | CA2 (0.68) | APEX1CA2ALDH1A1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| WO-2009035997-A2 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-5101069-A | PROCESS FOR THE PREPARATION OF HYDROXYETHYLSULFONYLNITRO- AND HYDROXYETHYLSULFONYLAMINO-BENZOIC ACIDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-03-31 | — | — | US | disclosed |
| US-4960929-A | Chemical intermediate for making fiber reactive azo dyes | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CNR1, CNR2, TRPV1 | APEX1 4287/4885CA2 743/4885CASP6 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.